Índice

• • ·E-cigarettes—new product, old tricks

    Página :1543

     
• • ·Evidence-based screening protocols for cervical cancer?

    Página :1544-1545

    Paolo Giorgi Rossi

     
• • ·Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors

    Página :1545-1546

    Gilda Varricchi, Maria Rosaria Galdiero, Valentina Mercurio, Domenico Bonaduce, Gianni Marone, Carlo G Tocchetti

     
• • ·Long-term follow-up care needed for children surviving cancer: still a long way to go

    Página :1546-1548

    Jeanette F Winther, Leontien Kremer

     
• • ·Interrogating molecular data for medulloblastoma risk stratification

    Página :1548-1549

    Elisabetta Ferretti, Agnese Po

     
• • ·Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?

    Página :1549-1551

    Katherine K Matthay

     
• • ·Fine-tuning chemotherapy in the era of dual HER2 targeting

    Página :1551-1554

    Sherene Loi

     
• • ·Evolution of monoclonal antibodies in multiple myeloma

    Página :1554-1555

    Pellegrino Musto

     
• • ·Lorlatinib: a new-generation drug for ALK-positive NSCLC

    Página :1555-1557

    Saiama N Waqar, Daniel Morgensztern

     
• • ·Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia

    Página :1557-1558

    Fernando Ramos

     
• • ·Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer

    Página :1558-1560

    Anna Fagotti, Giovanni Scambia

     
• • ·Biomarkers in renal-cell carcinoma: building on clinical paradigms

    Página :1560-1561

    Neeraj Agarwal, Roberto Nussenzveig, Sumanta K Pal

     
• • ·Pseudoprogression: fact or wishful thinking in neuro-oncology?

    Página :1561-1563

    David A Reardon, Michael Weller

     
• • ·Beyond resumption of the Japanese Government’s recommendation of the HPV vaccine

    Página :1563-1564

    Yutaka Ueda, Asami Yagi, Sayaka Ikeda, Takayuki Enomoto, Tadashi Kimura

     
• • ·Tailoring adjuvant treatment in patients with uterine cancer

    Página :e655

    Giorgio Bogani, Valentina Chiappa, Domenica Lorusso, Francesco Raspagliesi

    
• • ·Tailoring adjuvant treatment in patients with uterine cancer – Authors’ reply

    Página :e656

    Michael Frumovitz, Nadeem R Abu-Rustum

    
• • ·Maternal use of hormonal contraception and risk of childhood leukaemia

    Página :e657

    Yubin Cao, Chunjie Li, Longjiang Li

    
• • ·Maternal use of hormonal contraception and risk of childhood leukaemia

    Página :e658

    Yongmei Huang, Cande V Ananth

    
• • ·Maternal use of hormonal contraception and risk of childhood leukaemia – Authors’ reply

    Página :e659

    Marie Hargreave, Lina S Mørch, Klaus K Andersen, Jeanette F Winther, Kjeld Schmiegelow, Susanne K Kjaer

    
• • ·Cancer trends and burden in India

    Página :e660

    Manigreeva Krishnatreya

    
• • ·Cancer trends and burden in India

    Página :e661

    Manoj Kalita

    
• • ·Cancer trends and burden in India

    Página :e662

    Aju Mathew

    
• • ·Cancer trends and burden in India

    Página :e663

    Chandramohan K, Boben Thomas

    
• • ·Cancer trends and burden in India – Authors’ response

    Página :e664

    Prashant Mathur, Ravi Mehrotra, Christina Fitzmaurice, Preet K Dhillon, A Nandakumar, Lalit Dandona, India State-Level Disease Burden Initiative Cancer Collaborators

    
• • ·National cancer control plans

    Página :e665

    Brian D Nicholson, Bethany Shinkins, Sarah Price, Jan Y Verbakel, Sam Merriel, Society of Academic Primary Care Cancer Special Interest Group

    
• • ·National cancer control plans

    Página :e666

    Gail Garvey, Joan Cunningham

    
• • ·Correction to Lancet Oncol 2014; 15: 640–47

    Página :e667

    
• • ·Correction to Lancet Oncol 2017; 18: 52–62

    Página :e667

    
• • ·Correction to Lancet Oncol 2017; 18: 732–42

    Página :e667

    
• • ·Correction to Lancet Oncol 2017; 18: 1360–72

    Página :e667

    
• • ·Correction to Lancet Oncol 2017; 18: e638

    Página :e667

    
• • ·Correction to Lancet Oncol 2018; 19: 1437–48

    Página :e668

    
• • ·Correction to Lancet Oncol 2018; 19: 1480–92

    Página :e668

    
• • ·Correction to Lancet Oncol 2018; 19: 1516–29

    Página :e668

    
• • ·Neoadjuvant pembrolizumab in bladder cancer

    Página :e669

    Elizabeth Gourd

     
• • ·Surveillance imaging of Wilms’ tumours

    Página :e670

    Robert Stirrups

     
• • ·Maintenance olaparib in advanced ovarian cancer

    Página :e671

    Talha Khan Burki

     
• • ·Venetoclax with decitabine or azacitidine for AML

    Página :e672

    Manjulika Das

     
• • ·Promising new treatment for multiple myeloma

    Página :e673

    Elizabeth Gourd

     
• • ·Outcomes after minimally invasive surgery in cervical cancer

    Página :e674

    Talha Khan Burki

     
• • ·Elotuzumab in multiple myeloma

    Página :e675

    Talha Khan Burki

     
• • ·Immunotherapy toxicity predicted by circulating cytokines

    Página :e676

    Elizabeth Gourd

     
• • ·Mandatory bundled payment model for US cancer patients

    Página :e677

    Manjulika Das

     
• • ·European Society of Medical Oncology 2018 Congress

    Página :e678

    Alex Sklan

    Esquema Esquema  
• • ·60th ASTRO Annual Meeting

    Página :e679

    Cheryl Lai

    Esquema Esquema  
• • ·Carcinogenicity of some nitrobenzenes and other industrial chemicals

    Página :e681

    IARC Monographs Vol 123 Group, M Van den Berg, R Cattley, J W Cherrie, D C Dorman, J K Dunnick, J M Gohlke, J Jinot, H U Käfferlein, L Kopylev, M Matsumoto, T Nomiyama, K Ogawa, L Perbellini, H Sone, Y Grosse, K Z Guyton, M K Schubauer-Berigan, F El Ghissassi, V Bouvard, L Benbrahim-Tallaa, A Hall, A Paul, H Mattock, K Straif

    
• • ·Meta-analyses and RCTs in oncology—what is the right balance?

    Página :1565-1566

    Bishal Gyawali

     
• • ·Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets

    Página :1567-1568

    Tyler Stewart, Karin Finberg, Zenta Walther, Jeffrey L Sklar, Navid Hafez, Joseph P Eder, Karen Anderson, Frederick Wilson, Sarah B Goldberg

    Esquema Esquema  
• • ·Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study

    Página :1569-1578

    Talía Malagón, Shalini Kulasingam, Marie-Hélène Mayrand, Gina Ogilvie, Leah Smith, Céline Bouchard, Walter Gotlieb, Eduardo L Franco

    Resumen Resumen Esquema Esquema   
• • ·Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

    Página :1579-1589

    Joe-Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun-Vignes, Lisa Bastarache, Antoine Pariente, Aurélien Gobert, Jean-Philippe Spano, Justin M Balko, Marc P Bonaca, Dan M Roden, Douglas B Johnson, Javid J Moslehi

    Resumen Resumen Esquema Esquema   
• • ·Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort

    Página :1590-1601

    Todd M Gibson, Sogol Mostoufi-Moab, Kayla L Stratton, Wendy M Leisenring, Dana Barnea, Eric J Chow, Sarah S Donaldson, Rebecca M Howell, Melissa M Hudson, Anita Mahajan, Paul C Nathan, Kirsten K Ness, Charles A Sklar, Emily S Tonorezos, Christopher B Weldon, Elizabeth M Wells, Yutaka Yasui, Gregory T Armstrong, Leslie L Robison, Kevin C Oeffinger

    Resumen Resumen Esquema Esquema   
• • ·Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial

    Página :1602-1616

    Tobias Goschzik, Edward C Schwalbe, Debbie Hicks, Amanda Smith, Anja zur Muehlen, Dominique Figarella-Branger, François Doz, Stefan Rutkowski, Birgitta Lannering, Torsten Pietsch, Steven C Clifford

    Resumen Resumen Esquema Esquema   
• • ·Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

    Página :1617-1629

    Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita Castellani, Mark N Gaze, Alberto Garaventa, Andrew D J Pearson, Holger N Lode

    Resumen Resumen Esquema Esquema   
• • ·Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

    Página :1630-1640

    Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Vincent O Dezentjé, Irma M Oving, Aafke H Honkoop, Lidwine W Tick, Agnes J van de Wouw, Caroline M Mandigers, Laurence J van Warmerdam, Jelle Wesseling, Marie-Jeanne T Vrancken Peeters, Sabine C Linn, Gabe S Sonke, Dutch Breast Cancer Research Group (BOOG)

    Resumen Resumen Esquema Esquema   
• • ·Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

    Página :1641-1653

    Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D Anderson, Heather J Sutherland, Kwee Yong, Axel Hoos, Michele M Gorczyca, Soumi Lahiri, Zangdong He, Daren J Austin, Joanna B Opalinska, Adam D Cohen

    Resumen Resumen Esquema Esquema   
• • ·Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Página :1654-1667

    Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel, Gregory J Riely, Eng Huat Tan, Takashi Seto, Leonard P James, Jill S Clancy, Antonello Abbattista, Jean-François Martini, Joseph Chen, Gerson Peltz, Holger Thurm, Sai-Hong Ignatius Ou, Alice T Shaw

    Resumen Resumen Esquema Esquema   
• • ·Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

    Página :1668-1679

    Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel, Regina Herbst, Dominik Wolf, Claudia D Baldus, Uta Oelschlägel, Anke Mütherig, Lars Fransecky, Richard Noppeney, Gesine Bug, Katharina S Götze, Alwin Krämer, Tilmann Bochtler, Matthias Stelljes, Christoph Groth, Antje Schubert, Marika Mende, Friedrich Stölzel, Christine Borkmann, Anne Sophie Kubasch, Malte von Bonin, Hubert Serve, Mathias Hänel, Ulrich Dührsen, Johannes Schetelig, Christoph Röllig, Michael Kramer, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede

    Resumen Resumen Esquema Esquema   
• • ·Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

    Página :1680-1687

    Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen, W Glenn McCluggage, Tim Perren, Pierluigi Benedetti Panici, Gemma Kenter, Antonio Casado, Cesar Mendiola, Gavin Stuart, Nick S Reed, Sean Kehoe, EORTC, MRC CHORUS study investigators, Claes Tropé G., Stephen Dobbs, Sharadah Essapen, P. Hoskins, John Green, E. Gilby, M. Van Baal, Jeremy Twigg, Maria E.L. Van Der Burg, Keith Godfrey, Angel J. Lacave, R. Angioli, Rahul Nath, Kirk Chin, Charles Redman, R. Lotocki, Adeola Olaitan, B. Mosgaard, G. Rustin, Thomas Ind, Mojca Persic, Martin Hogg, J. Van Der Velden, J. Ledermann, Peter Sykes Peter Sykes, Krishnawam Madhavan, P. Kannisto, Vicky Hird, A. Evans, R. Sandvei R., P. Gauthier, D.J. Cruickshank, P.B. Ottevanger, Sheila Pearson, Henry Kitchener, Marcia Hall, P. Bessette, S. Pecorelli, E. Gerdin, Tito Lopes, Andrew Fish, Clare Barlow., K. Van Eygen, A. Floquet, B. Tholander, N. Gul, Robert Gornall, David Luesley, Philip Kirwan, Paul Symonds, Richard Henry, David Poole, Ian McNeish, Mark Hocking, Al Sammaraie, P. Speiser, E. Leblanc, J.A. Green, C.F. De Oliveira, R. Grimshaw, P. Zola, David Parkin, David Luesley, Martin Lamb, Anne Hong, Alan Gillespie, Abdel Hamid, Ahmed Ahmed, M. Plante, B. De Valk, A. Nordin, Andrew Clamp, David Perez, Graham Dark Graham Dark, Michelle Ferguson, Carol MacGregor, Geraldine Skailes, Rachel Jones, Alan Gillespie, G. Cawdell, Simon Leeson, L. Elit, C. Dittrich, W. Gotlieb, David Poole, John Cullimore, Barbara Crosse, Paul Ridley, Anthony Head, Joaquin Nieto, Saif Awwad, Dirk Brinkmann, Damian Eustace, Andrew Hindley, D. Katsaros, C. Popadiuk, Tome Kristeller, C. Redman, S. Chan, C. Marth, Dennis Yiannakis, Kate Lankaster, Gareth Beynon, Anwar Suhail, Fernando Indrajit, Anne Hong, Mary Quigley, Olu Adeyemi, Mojca Persic, Fiona Lofts, Orla McNally, Amanda Tristam, Martin Lee, R. Counsell, N. Gleeson, A. Papadopoulos, T. Maggino, A. Honkoop, P. Ghatage, J.B. Vermorken, J. De Greve, K. Boman, E Petru, F. Amant

    Resumen Resumen Esquema Esquema   
• • ·Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

    Página :1688-1698

    Martin H Voss, Albert Reising, Yuan Cheng, Parul Patel, Mahtab Marker, Fengshen Kuo, Timothy A Chan, Toni K Choueiri, James J Hsieh, A Ari Hakimi, Robert J Motzer

    Resumen Resumen Esquema Esquema   
• • ·Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer

    Página :e683

    David T Miyamoto, Kent W Mouw, Felix Y Feng, William U Shipley, Jason A Efstathiou

    Resumen Resumen Esquema Esquema  
• • ·Consensus on molecular imaging and theranostics in prostate cancer

    Página :e696

    Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, Karim Fizazi, Silke Gillessen, Sam Gledhill, Uwe Haberkorn, Ken Herrmann, Rodney J Hicks, Frederic Lecouvet, Rodolfo Montironi, Piet Ost, Joe M O’Sullivan, Anwar R Padhani, Jack A Schalken, Howard I Scher, Bertrand Tombal, R Jeroen A van Moorselaar, Heindrik Van Poppel, Hebert Alberto Vargas, Jochen Walz, Wolfgang A Weber, Hans-Jürgen Wester, Wim J G Oyen

    Resumen Resumen Esquema Esquema   
• • ·Defining priority medical devices for cancer management: a WHO initiative

    Página :e709

    Adriana Velazquez Berumen, Gabriela Jimenez Moyao, Natalia M Rodriguez, André M Ilbawi, Antonio Migliore, Lawrence N Shulman

    Resumen Resumen Esquema Esquema   
• • ·Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

    Página :e720

    Jean Jacques Grob, Claus Garbe, Paolo Ascierto, James Larkin, Reinhard Dummer, Dirk Schadendorf

    Resumen Resumen Esquema Esquema
• • ·Lung squamous carcinoma involving the lip and cheek

    Página :e726

    Binjie Yan, Fang Wu, Nong Yang, Yongchang Zhang